SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56: 25586.
  • 2
    Griggs RC, Askanas V, di Mauro S, Engel A, Karpati G, Mendell JR, et al. Inclusion body myositis and myopathies [review]. Ann Neurol 1995; 38: 70513.
  • 3
    Oddis CV, Conte CG, Steen VD, Medsger TA Jr. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990; 17: 132934.
  • 4
    Guidance for industry: clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis (RA). US Department of Health and Human Services Food and Drug Administration; 1999. p. 147.
  • 5
    Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al, and the International Myositis Outcome Assesment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001; 40: 126273.
  • 6
    Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, et al, and the Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis [review]. Rheumatology (Oxford) 2003; 42: 14529.
  • 7
    Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al, for the International Myositis Assesment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50: 228190.
  • 8
    Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al, and the International Myositis Assessment and Clinical Studies Group. Defining clinical improvement in adult and juvenile myositis [review]. J Rheumatol 2003; 30: 60317.
  • 9
    Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Culper E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56: 3237.
  • 10
    Adams EM, Pucino F, Yarboro C, Hicks JE, Thornton B, McGarvey C, et al. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J Rheumatol 1999; 26: 35260.
  • 11
    Al-Mayouf S, Al-Mazyed A, Bahabr S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 2000; 19: 13841.
  • 12
    Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 1981; 24: 458.
  • 13
    Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med 1980; 92: 3659.
  • 14
    Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 1628.
  • 15
    Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Ziza JM, et al. Intravenous immunoglobulin for polymyositis and dermatomyositis [published erratum appears in Lancet 1990;336:518]. Lancet 1990; 336: 116.
  • 16
    Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002; 46: 46774.
  • 17
    Cherin P, Piette JC, Wechsler B, Bletry O, Ziza JM, Laraki R, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994; 21: 10927.
  • 18
    Cherin P, Auperin I, Bussel A, Pourrat J, Herson S. Plasma exchange in polymyositis and dermatomyositis: a multicenter study of 57 cases. Clin Exp Rheumatol 1995; 13: 2701.
  • 19
    Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48: 7126.
  • 20
    Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002; 61: 3741.
  • 21
    Tawil R and the Muscle Study Group. Randomized pilot trial of β INF1a (Avonex) in patients with inclusion body myositis. Neurology 2001; 57: 156670.
  • 22
    Heckmatt J, Hasson N, Saunders C, Thompson N, Peters AM, Cambridge G, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; 1: 10636.
  • 23
    Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91: 16972.
  • 24
    Leff RL, Miller FW, Hicks J, Fraser DD, Plotz PH. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (Baltimore) 1993; 72: 22535.
  • 25
    Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1998; 65: 10710.
  • 26
    Miller LC, Sisson BA, Tucker LB, de Nardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992; 35: 11439.
  • 27
    Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992; 326: 13804.
  • 28
    Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353: 17623.
  • 29
    Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis: four year review of nine cases. Arch Dis Child 1995; 72: 258.
  • 30
    Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000; 29: 95102.
  • 31
    Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998; 41: 3929.
  • 32
    Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000; 247: 228.
  • 33
    Cronin ME, Miller FW, Hicks JE, Dalakas M, Plotz PH. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989; 16: 12258.
  • 34
    Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 19932000.
  • 35
    Delbecq A, van de Ven A, Gustafson D. Group techniques for program planning: a guide to nominal group and Delphi processes. Glenville (IL): Scott, Foresman; 1975.
  • 36
    Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 4037.
  • 37
    Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 3447.
  • 38
    Miller FW. Inflammatory myopathies: polymyositis, dermatomyositis, and related conditions. In: KoopmanW, MorelandL, editors. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1593620.
  • 39
    Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al, and the International Myositis and Clinical Studies Group. International consensus outcome measures for patients with idiopathic inflammatory myopathies: development and initial validation of myositis activity and damage indices in patients with adult onset disease [review]. Rheumatology (Oxford) 2003; 42: 4954.
  • 40
    Rider LG. Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002; 28: 93577.
  • 41
    Feldman BM, Wang E, Willan A, Szalai JP. The randomized placebo-phase design for clinical trials. J Clin Epidemiol 2001; 54: 5507.
  • 42
    Guidance for industry: E10 choice of control group and related issues in clinical trials. US Department of Health and Human Services Food and Drug Administration; 2001. p. 133.
  • 43
    Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 22904.
  • 44
    White B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn JH, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. Arthritis Rheum 1995; 38: 35160.